A small interfering RNA targeting proteinase‐activated receptor‐2 is effective in suppression of tumor growth in a Panc1 xenograft model

Proteinase‐activated receptor‐2 (PAR‐2), which is a G protein‐coupled receptor, is activated in inflammatory processes and cell proliferation. We previously demonstrated that an anti‐PAR‐2 antibody suppresses proliferation of human pancreatic cells in vitro. However, there have been no studies of PAR‐2 signaling pathways in vivo. The aim of this study was to determine whether blockade of PAR‐2 by RNA interference influences pancreatic tumor growth. We originally constructed small interfering RNAs (siRNAs) targeting human PAR‐2, and performed cell proliferation assays of Panc1 human pancreatic cancer cell line with these siRNAs. Intratumoral treatment with these PAR‐2 siRNAs and atelocollagen was also performed in a xenograft model with nude mice and Panc1 cells. siRNAs against human PAR‐2 inhibited proliferation of Panc1 cells, whereas control scramble siRNAs had no effect on proliferation. The PAR‐2 siRNAs dramatically suppressed tumor growth in the xenograft model. PAR‐2‐specific siRNA inhibited growth of human pancreatic cancer cells both in vitro and in vivo. Blockade of PAR‐2 signaling by siRNA may be a novel strategy to treat pancreatic cancer. © 2007 Wiley‐Liss, Inc.

[1]  Ernst Wagner,et al.  Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[2]  C. Degott,et al.  Mucin gene expression in intraductal papillary‐mucinous pancreatic tumours and related lesions , 2002, The Journal of pathology.

[3]  T. Salo,et al.  Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. , 2003, Biochemistry.

[4]  D. Heilman,et al.  Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. , 2000, Carcinogenesis.

[5]  M. Nishibori,et al.  Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. , 2005, Journal of pharmacological sciences.

[6]  S. Kitano,et al.  Protease‐activated receptor‐2 regulates cell proliferation and enhances cyclooxygenase‐2 mRNA expression in human pancreatic cancer cells , 2005, Journal of surgical oncology.

[7]  S. Coughlin,et al.  Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. , 1996, The Biochemical journal.

[8]  S. Fan,et al.  Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  N. Kosaka,et al.  Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. , 2004, Nucleic acids research.

[10]  M. Laburthe,et al.  Trypsin is produced by and activates protease-activated receptor-2 in human cancer colon cells: evidence for new autocrine loop. , 2002, Life sciences.

[11]  M. Ogawa,et al.  Expression of proteinase-activated receptor-2 in human pancreatic cancer: a possible relation to cancer invasion and induction of fibrosis. , 2003, International journal of oncology.

[12]  M. Ohmuraya,et al.  Proinflammatory Role of Trypsin and Protease-activated Receptor-2 in a Rat Model of Acute Pancreatitis , 2005, Pancreas.

[13]  T. Sawada,et al.  A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. , 2004, International journal of oncology.

[14]  J. Wallace,et al.  Protease-activated receptors in inflammation, neuronal signaling and pain. , 2001, Trends in pharmacological sciences.

[15]  G. Hannon,et al.  Unlocking the potential of the human genome with RNA interference , 2004, Nature.

[16]  M. Thun Aspirin, NSAIDs, and digestive tract cancers , 1994, Cancer and Metastasis Reviews.

[17]  T. Salo,et al.  Down‐regulation of trypsinogen‐2 expression by chemically modified tetracyclines: Association with reduced cancer cell migration , 2000, International journal of cancer.

[18]  Leaf Huang,et al.  Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. , 2006, Molecular pharmaceutics.

[19]  H. Körner,et al.  Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis , 2006, The Journal of pathology.

[20]  Hiroyuki Yamamoto,et al.  Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer , 2003, The Journal of pathology.

[21]  H. Kitagawa,et al.  Protease-activated receptor-2 expression and the role of trypsin in cell proliferation in human pancreatic cancers. , 2003, International journal of oncology.

[22]  J. G. Patton,et al.  siRNA therapeutics: big potential from small RNAs , 2005, Gene Therapy.

[23]  T. Ochiya,et al.  New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet , 1999, Nature Medicine.

[24]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[25]  G I Murray,et al.  Matrix metalloproteinases in tumour invasion and metastasis , 1999, The Journal of pathology.

[26]  K. Scanlon Cancer gene therapy: challenges and opportunities. , 2004, Anticancer research.

[27]  C. Haglund,et al.  Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer , 2006, Journal of Clinical Pathology.

[28]  Y. Iwashita,et al.  Dendritic cell immunotherapy with poly(d,l‐2,4‐diaminobutyric acid)‐mediated intratumoral delivery of the interleukin‐12 gene suppresses tumor growth significantly , 2005, Cancer science.

[29]  D. Sørensen,et al.  Cationic liposome-mediated delivery of siRNAs in adult mice. , 2003, Biochemical and biophysical research communications.

[30]  B. Strömbeck,et al.  Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. , 1995, European journal of biochemistry.

[31]  S. Hawthorne,et al.  Amplification of MMP‐2 and MMP‐9 production by prostate cancer cell lines via activation of protease‐activated receptors , 2004, The Prostate.

[32]  Y. Yuzawa,et al.  A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics , 2004, Cancer Research.

[33]  T. Goi,et al.  Expression of protease activated receptor‐2 (PAR‐2) in gastric cancer , 2006, Journal of surgical oncology.

[34]  P. Billings,et al.  Effects of Bowman-Birk Inhibitor on Rat Colon Carcinogenesis , 2002, Nutrition and cancer.

[35]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.

[36]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[37]  A. Harel-Bellan,et al.  SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. , 2003, Cancer research.

[38]  R. Surabhi,et al.  Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  C. Wahlestedt,et al.  Molecular cloning of a potential proteinase activated receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Iggo,et al.  Induction of an interferon response by RNAi vectors in mammalian cells , 2003, Nature Genetics.

[41]  S. M. Baker,et al.  Characterization of Protease-activated Receptor-2 Immunoreactivity in Normal Human Tissues , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[42]  N. Mackman,et al.  Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. , 2004, Critical care medicine.

[43]  M. Laburthe,et al.  Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2 , 2001, British Journal of Cancer.

[44]  G. D. Hunter,et al.  Proteinase-activated receptors. , 2001, Pharmacological reviews.

[45]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[46]  A. Masamune,et al.  Protease-Activated Receptor-2-Mediated Proliferation and Collagen Production of Rat Pancreatic Stellate Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.

[47]  B. M. Mueller,et al.  Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. , 2006, Biochemical and biophysical research communications.

[48]  S. Kitano,et al.  Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. , 2005, International journal of oncology.

[49]  M. Hollenberg,et al.  Signal Transduction for Proteinase-Activated Receptor-2-Triggered Prostaglandin E2 Formation in Human Lung Epithelial Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.

[50]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[51]  Mouldy Sioud,et al.  Gene silencing by systemic delivery of synthetic siRNAs in adult mice. , 2003, Journal of molecular biology.

[52]  T. Carter,et al.  Cyclooxygenase-2 Induction and Prostacyclin Release by Protease-activated Receptors in Endothelial Cells Require Cooperation between Mitogen-activated Protein Kinase and NF-κB Pathways* , 2006, Journal of Biological Chemistry.

[53]  Penny A. Johnson,et al.  Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus , 2006, BMC Cancer.

[54]  M. Ogawa,et al.  Signal of proteinase-activated receptor-2 contributes to highly malignant potential of human pancreatic cancer by up-regulation of interleukin-8 release. , 2006, International journal of oncology.